Noble Capital Markets initiated coverage on Nutriband with a new price target
$NTRB
Industrial Specialties
Health Care
Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $13.00 | Outperform | Noble Capital Markets |
SC 13D/A - NutriBand Inc. (0001676047) (Subject)
SC 13G - NutriBand Inc. (0001676047) (Subject)
SC 13G - NutriBand Inc. (0001676047) (Subject)
ORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders highlighting the company's achievements in 2024 and the outlook for 2025. Dear Fellow Shareholders, As we close out 2024, I want to extend my deepest gratitude to you, our loyal shareholders, for your continued trust and support. This year has been one of exceptional progress, strategic execution, and transformative milestones for Nutriband. We remain steadfast in our mission to enhance patient safety through innovative transdermal technologies, with a particular focus on combating the opioid crisis and improving
Nutriband's abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband is targeting to file for FDA approval for AVERSA™ Fentanyl in the first half of 2025. ORLANDO, Fla., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has completed the registration requirements to extend its Chinese patent to Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Macao IP Office has assigned number J
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for first half of 2025. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record third quarter reporting revenue of $645,796 USD, up 50.94%
8-K - NutriBand Inc. (0001676047) (Filer)
8-K - NutriBand Inc. (0001676047) (Filer)
DEF 14A - NutriBand Inc. (0001676047) (Filer)
The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo
Nutriband among the first issuers to dual list on UpstreamORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".Global investors can now trade by downloading Upstream from their preferred app sto
Trading scheduled to Commence on Upstream January 5, 2023ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval."We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.The dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, u
4 - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
4 - NutriBand Inc. (0001676047) (Issuer)
Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00